[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:pancreatic-neuroendocrine-tumor:somatostatin-receptor":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Pancreatic Neuroendocrine Tumor","Somatostatin Receptor",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05687123","Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.295160Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06663072","Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors",[12],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.804469Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06016855","Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors",[26],"Phase 4","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.860078Z"]